Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO)

T Tomás Pascual M Maria Vidal J Juan M. Cejalvo E Estela Vega E Esther Sanfeliu G Guillermo Villacampa S Sergi Ganau A Ana María Julve Parreño E Esther Zamora I Ignacio Miranda A Ana Delgado B Begoña Bermejo E Elia Seguí F Fara Brasó-Maristanty L Luis de la Cruz-Merino M Manel Juan P Patricia Galván X Xavier Gonzàlez-Farré S Samyukta Chillara P Patricia Villagrasa A Adam D. Pfefferle C Constandina E. O’Connell J Juan M. Ferrero-Cafiero M Mafalda Oliveira (Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, Barcelona) C Charles M. Perou A Aleix Prat

Article Details

Volume / Issue Vol. 17, Issue 1
Published February 16, 2026
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (26)

T

Tomás Pascual

M

Maria Vidal

J

Juan M. Cejalvo

E

Estela Vega

E

Esther Sanfeliu

G

Guillermo Villacampa

S

Sergi Ganau

A

Ana María Julve Parreño

E

Esther Zamora

I

Ignacio Miranda

A

Ana Delgado

B

Begoña Bermejo

E

Elia Seguí

F

Fara Brasó-Maristanty

L

Luis de la Cruz-Merino

M

Manel Juan

P

Patricia Galván

X

Xavier Gonzàlez-Farré

S

Samyukta Chillara

P

Patricia Villagrasa

A

Adam D. Pfefferle

C

Constandina E. O’Connell

J

Juan M. Ferrero-Cafiero

M

Mafalda Oliveira

Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, Barcelona

C

Charles M. Perou

A

Aleix Prat